Journal ArticleOPEN ACCESS

Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type

Clinical Case Reports (2019) 7(5) 964-967
DOI: 10.1002/ccr3.2137
4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) has a poor prognosis. R-CHOP with or without radiotherapy is the available recommendations for first-line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second-line treatment of relapsed PCDLBCL-LT.

Author supplied keywords

Cite

CITATION STYLE

APA

Al Dhafiri, M., Sicre de Fontbrune, F., Marinho, E., Deschamps, L., Di-Lucca, J., Crickx, B., & Descamps, V. (2019). Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type. Clinical Case Reports, 7(5), 964–967. https://doi.org/10.1002/ccr3.2137

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free